Tildacerfont cocrystal formulations
Patent Information
- Application Number
- PCT/US2024/030822
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-28
Smart Images

Figure IMGF000003_0001 
Figure IMGF000005_0001 
Figure IMGF000028_0001
Abstract
Description
TILDACERFONT COCRYSTAL FORMULATIONSCROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 468,764 filed May 24, 2023, which is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION
[0002] Tildacerfont is an antagonist of corticotropin releasing factor (CRF), which can be a useful therapeutic agent for treating congenital adrenal hyperplasia (CAH). Tildacerfont was previously synthesized in a crystalline form, which can cause solubility issues during formulation. This is problematic as low solubility can lead to poor bioavailability and inconsistent drug absorption, which can affect the drug's efficacy. Synthesis of tildacerfont with a co-crystal such as oxalic acid can result in better formulations as an Active Pharmaceutical Ingredient (API). However, the co-crystal of tildacerfont and oxalic acid are very bulky and cohesive, demonstrating poor / passable flow properties for API manufacturing, distribution and dosage and content uniformity.
[0003] Flow property generally refers to the ability of a powdered material to flow, and is related to cohesion of the compound, and can depend on various factors, such as, but not limited to particle size, moisture, and temperature. Flow properties of drugs can affect manufacturing efficiency, packaging and dispensing, and more importantly, drug and content uniformity. Drug uniformity of flow property is important for maintaining the desired therapeutic effect and content uniformity is important for affecting the drug’s efficacy.
[0004] Thus, new formulations for the drug are necessary in order to improve the flow properties of the co-crystal of tildacerfont and oxalic acid.SUMMARY
[0005] Provided herein are pharmaceutical compositions comprising Compound 1 and low moisture pharmaceutically acceptable excipients, methods of making the pharmaceutical compositions, and methods of treatment using the pharmaceutical compositions.
[0006] One embodiment provides a pharmaceutical composition comprising a co-crystal of Compound 1 and oxalic acid, and at least one pharmaceutically acceptable excipient, wherein the pharmaceutically acceptable excipient has a low moisture content of less than 5% loss on drying (LOD) w / w, wherein Compound 1 has the following structure:
[0007] One embodiment provides a method of preparing the pharmaceutical composition described herein, the method comprising mixing a solid co-cry stal of Compound 1 and oxalic acid with a solid pharmaceutically acceptable excipient to form a powder blend.
[0008] One embodiment provides a method of treating testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART) in a subject in need thereof, comprising administering to the subject the pharmaceutical composition as described herein.
[0009] One embodiment provides a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, comprising administering to the subject the pharmaceutical composition as described herein.
[0010] One embodiment provides a method of improving hyperandrogenic systems in a subject in need thereof, comprising administering to the subject the pharmaceutical composition as described herein.
[0011] One embodiment provides a method of treating menstrual irregularity, ovulatory dysfunction or infertility, in a subject in need thereof, comprising administering to the subject the pharmaceutical composition as described herein.
[0012] One embodiment provides a method of improving metabolic symptoms in a subject in need thereof, comprising administering to the subject the pharmaceutical composition as described herein.
[0013] One embodiment provides a method of treating polycystic ovary syndrome with functional ovarian hyperandrogenism and functional adrenal hyperandrogenism (PCOS-FOH + FAH) in a subject in need thereof, comprising administering to the subject the pharmaceutical composition as described herein.
[0014] One embodiment provides a method of treating polycystic ovary syndrome with functional adrenal hyperandrogenism (PCOS-FAH) in a subject in need thereof, administering to the subject the pharmaceutical composition as described herein.
[0015] One embodiment provides a method of treating endometriosis or improving the symptoms of endometriosis in a subject in need thereof, comprising administering to the subject the pharmaceutical composition as described herein.
[0016] One embodiment provides a use of a pharmaceutical composition as described herein, in the manufacture of a medicament for the treatment of congenital adrenal hyperplasia (CAH).DETAILED DESCRIPTION
[0017] Tildacerfont (Compound 1) is a potent antagonist of Corticotropin-releasing hormone receptor 1 (CRF1). CRF1 antagonists may be useful in the treatment of various diseases, conditions, and disorders for which abnormal CRF1 activity plays a role.
[0018] Different crystalline forms of a small molecule drug candidate, such as a CRF1 antagonist, may have different physical properties, including melting point, apparent solubility, dissolution rate, optical and mechanical properties, vapor pressure, and density. These properties may have an effect on the ability to process or manufacture a drug substance and the drug product. Moreover, differences in these properties can and often lead to different pharmacokinetics profiles for different polymorphic forms of a drug. Polymorphism may affect the quality, safety, and / or efficacy of a drug product, such as a CRF1 antagonist. Thus, there still remains a need for co-crystalline compositions of tildacerfont and formulations of the co-crystal with good stability and shelf-life.
[0019] The present disclosure addresses this need and provides related advantages as well.Pharmaceutical Compositions
[0020] Provided herein is a pharmaceutical composition comprising a co-crystal of Compound 1 and oxalic acid, and at least one pharmaceutically acceptable excipient, wherein the pharmaceutically acceptable excipient has a low moisture content.
[0021] Provided herein is a pharmaceutical composition comprising a co-crystal of Compound 1 and oxalic acid, and at least one pharmaceutically acceptable excipient, wherein the pharmaceutically acceptable excipient has a low moisture content of less than 5% loss on drying (LOD) w / w, wherein Compound 1 has the following structure:
[0022] The moisture content of the pharmaceutically acceptable excipients can be measured by any technique known by one of skill in the art. For example, a method that may be used is measuring the loss on drying of the solids. In some embodiments, the pharmaceutically acceptable excipient has a low moisture content of less than 5% LOD weight / weight (w / w). In some embodiments, the pharmaceutically acceptable excipient has a low moisture content of less than 4% LOD w / w. In some embodiments, the pharmaceutically acceptable excipient has a low moisture content of less than 3% LOD w / w. In some embodiments, the pharmaceutically acceptable excipient has a low moisture content of less than 2% LOD w / w. In some embodiments, the pharmaceutically acceptable excipient has a low moisture content of less than 1% LOD w / w.
[0023] The pharmaceutical composition described herein can comprise more than one pharmaceutically acceptable excipient. In some embodiments, there are at least two pharmaceutically acceptable excipients. In some embodiments, there are at least three pharmaceutically acceptable excipients. In some embodiments, there are at least four pharmaceutically acceptable excipients. In some embodiments, there are at least five pharmaceutically acceptable excipients.
[0024] The pharmaceutically acceptable excipients useful in the present invention have low moisture content. In some embodiments, each pharmaceutically acceptable excipient is microcrystalline cellulose (MCC), sodium lauryl sulfate, copovidone, magnesium stearate, dicalcium phosphate anhydrous, or silicone dioxide. In some embodiments, the pharmaceutically acceptable excipient is microcrystalline cellulose (MCC), sodium lauryl sulfate, magnesium stearate, or dicalcium phosphate anhydrous.
[0025] In some embodiments, the MCC is AceCell 112, Pharmacel 112, Avicel PH 200, Vivapur 200 XLM, or Vivapur 14. In some embodiments, the MCC is Avicel PH 200, Vivapur 200 XLM, or Vivapur 14. In some embodiments, the MCC is Avicel PH 200 or Vivapur 14. In some embodiments, the MCC is Avicel PH 200. In some embodiments, the MCC is Vivapur 14.
[0026] Having lower moisture content may be useful for the formulations of the pharmaceutical composition for stability of the co-crystal described herein. In some embodiments, the pharmaceutical composition further comprises a moisture barrier between the co-crystal and the pharmaceutically acceptable excipient. In some embodiments, the moisture barrier is a moisture barrier film coating. In some embodiments, the film coating is one or more synthetic polymers. Examples of synthetic polymers include, but are not limited to water-soluble polymers, water-insoluble polymers, and entero-soluble polymers.
[0027] In some embodiments, the film coating is a water-soluble polymer. In some embodiments, the water-soluble polymer is polyvinyl alcohol (PVA), hydroxypropyl methyl cellulose (HPMC), hydroxyethyl cellulose (HEC), polyvinyl alcohol-polyethylene glycol (PVA-PEG), methyl methacrylate and diethylamino-ethyl ethacrylate copolymer dispersion, or hydroxypropyl cellulose (HPC).
[0028] In some embodiments the film coating is a water-insoluble polymer. In some embodiments, the water-insoluble polymer is polyvinyl acetate, ethyl cellulose, cellulose acetate, amino methacrylate copolymer, or poly (ethyl acrylate-co-methyl methacrylate) 2:1 .
[0029] In some embodiments, the film coating is an entero-soluble polymer. In some embodiments, the entero-soluble polymer is shellac, cellulose acetate phthalate (CAP), cellulose acetate butyrate (CAB), methacrylic acid copolymer Type A, methacrylate acid copolymer Type B, methacrylic acid copolymer Type C, methacrylic acid copolymer, amino diethyl-methacrylate copolymer, acrylic acid copolymer, sodium alginate, or carb oxy methyl cellulose (CMC).
[0030] The amount of Compound 1 in the pharmaceutical composition can be any suitable amount known by one of skill in the art. In some embodiments, Compound 1 is in an amount of about 1 mg to 500 mg. In some embodiments, Compound 1 is in an amount of about 10 mgto 250 mg. In some embodiments, Compound 1 is in an amount of about 10 mg to 150 mg. In some embodiments, Compound 1 is in an amount of about 10 mgto 100 mg. In some embodiments, Compound 1 is in an amount of about 25 mg to 100 mg. In some embodiments, Compound 1 is in an amount of about 25 mgto 75 mg. In some embodiments, Compound 1 is in an amount of about 50 mg.
[0031] The pharmaceutical compositions described may have good stability for a reasonable time as determined by one of skill in the art. In some embodiments, the pharmaceutical composition is shelf-stable for at least 2 weeks. In some embodiments, the pharmaceutical composition is shelf-stable for at least one month. In some embodiments, the pharmaceutical composition is shelf-stable for at least two months. In some embodiments, thepharmaceutical composition is shelf-stable for at least three months. In some embodiments, the pharmaceutical composition is shelf-stable for at least four months. In some embodiments, the pharmaceutical composition is shelf-stable for at least five months. In some embodiments, the pharmaceutical composition is shelf-stable for at least six months. In some embodiments, the pharmaceutical composition is shelf-stable for at least a year.
[0032] The co-crystal of Compound 1 and oxalic acid can be characterized by X-ray powder diffraction pattern (XRPD) and by differential scanning calorimetry (DSC) thermogram. In some embodiments, the co-crystal has an X-ray powder diffraction pattern (XRPD) comprising peaks at 10.84 ± 0.2° 2-9, 15.96 ± 0.2° 2-9, 23.44 ± 0.2° 2-9, and 24.80 ± 0.2° 2-9, and as measured by XRPD using an X-ray wavelength of 0.71073 A. In some embodiments, the XRPD further comprises at least one peak selected from 5.44 ± 0.2° 2-9, 20.78 ± 0.2° 2-9, 22.74 ± 0.2° 2-9, 23.04 ± 0.2° 2-9, 26.80 ± 0.2° 2-9, and 28.86 ± 0.2° 2-9, and as measured by X-ray powder diffraction using an X-ray wavelength of 0.71073 A. In some embodiments, the XRPD further comprises at least five peaks selected from 8.82 ± 0.2° 2-9, 11.70 ± 0.2° 2-9, 14.60 ± 0.2° 2-9, 15.56 ± 0.2° 2-9, 16.70 ± 0.2° 2-9, 18.82 ± 0.2° 2-9, 19. 18 ± 0.2° 2-9, 20.02 ± 0.2° 2-9, 20.50± 0.2° 2-9, 21 ,72± 0.2° 2-9, 25.52± 0.2° 2-9, 25.92 ± 0.2° 2-9, 26.94 ± 0.2° 2-9, and 28.00 ± 0.2° 2-9, and as measured by X-ray powder diffraction using an X-ray wavelength of 0.71073 A.
[0033] In some embodiments, the co-crystal is characterized by differential scanning calorimetry (DSC) thermogram comprising an endotherm in the range of about 160 °C to 170 °C. In some embodiments, the co-crystal is characterized by a DSC thermogram comprising an endotherm with an onset of about 164 °C and a peak of about 166 °C.
[0034] The pharmaceutical composition described herein can be in any suitable oral dosage form known by one of skill in the art. Suitable oral dosage forms include, for example, tablets, pills, sachets, or capsules of hard or soft gelatin, methylcellulose or of another suitable material easily dissolved in the digestive tract. In some embodiments, the suitable oral dosage is in a capsule. In some embodiments, the pharmaceutical composition is in a capsule. In some embodiments, the capsule is a hard gelatin capsule or hydroxyl propyl methyl cellulose (HPMC) capsule. In some embodiments, the capsule is a hard gelatin capsule. In some embodiments, the capsule is a hydroxyl propyl methyl cellulose (HPMC) capsule.Methods of Preparing Pharmaceutical Compositions
[0035] Provided herein is a method of preparing the pharmaceutical compositions described herein. Provided herein is a method of preparing the pharmaceutical composition asdescribed herein, the method comprising mixing a solid co-cry stal of Compound 1 and oxalic acid with a solid pharmaceutically acceptable excipients to form a powder blend.
[0036] The powder blend can be directly filled into a capsule (direct blending method). The powder blend can be made into slugs followed by milling to form granules, which are then filled into the capsule (dry granulation method). The powder blend can be added to organic solvent and then dried and milled to form granules, which are then filled into the capsule (wet granulation method).
[0037] The ratio of the pharmaceutically acceptable excipient to Compound 1 can be any suitable ratio, such as but not limited to a 1 : 1 to 1 : 10 ratio. In some embodiments, the ratio of the pharmaceutically acceptable excipient to Compound 1 is about a 1 :1 to 1 :8 ratio. In some embodiments, the ratio of the pharmaceutically acceptable excipientto Compound 1 is about a 1 : 1 to 1 :6 ratio. In some embodiments, the ratio of the pharmaceutically acceptable excipientto Compound 1 is about a 1 :1 to 1 :4 ratio. In some embodiments, the ratio of the pharmaceutically acceptable excipient to Compound 1 is about a 1 :2 to 1 :4 ratio. In some embodiments, the ratio of the pharmaceutically acceptable excipientto Compound 1 is about a 1 :3 to 1 :4 ratio.
[0038] In some embodiments, the method further comprises granulating the powder blend to form granules. Granules can be formed by either the dry granulation or the wet granulation method. In some embodiments, the granules are formed by dry granulation. In some embodiments, the dry granulation comprises compressing the powder blend into slugs. In some embodiments, the powder blend is compressed into slugs using a compression machine. In some embodiments, the slug is then milled using co-mill to form granules. In some embodiments, the powder blend is compressed using a compression machine and milled using co-mill.
[0039] In some embodiments, the method further comprises coating Compound 1 onto an inert material such as but not limited to sugar beads and microcrystalline cellulose (MCC), followed by a moisture barrier for improved stability.
[0040] In some embodiments, the granules are formed by wet granulation. In some embodiments, the wet granulation comprises using a solvent on the powder blend and then drying it in the oven. Afterwards, the dried solid is then milled to form the granules. In some embodiments, wet granulation comprises: (a) using a solvent on the powder blend; then (b) drying in the oven; and (c) milled using co-mill to form the granules.
[0041] The granules or powder blend can be filled in any suitable capsule. In some embodiments, the granules are filled in a capsule. In some embodiments, the capsule is a hardgelatin capsule or hydroxyl propyl methyl cellulose (HPMC) capsule. In some embodiments, the capsule is a hard gelatin capsule. In some embodiments, the capsule is a HPMC capsule.
[0042] In some embodiments, the powder blend is filled in a capsule. In some embodiments, the powder blend is filled in a hard gelatin capsule or hydroxyl propyl methyl cellulose (HPMC) capsule. In some embodiments, the powder blend is filled in a hard gelatin capsule. In some embodiments, the powder blend is filled in a HPMC capsule.
[0043] The capsule size can be any suitable capsule size, for example, but not limited to, capsule size 00 to capsule size 4. In some embodiments, the capsule size is capsule size 00 to capsule size 3. In some embodiments, the capsule size is capsule size 0 to capsule size 2. In some embodiments, the capsule size is capsule size 0. In some embodiments, the capsule size is capsule size 1. In some embodiments, the capsule size is capsule size 2.Methods of Treatment
[0044] Provided herein are methods of treatment for diseases and disorders. In some embodiments, the diseases and disorders are tumors. In some embodiments, the diseases and disorders are genetic disorders.
[0045] Provided herein is a method of treating testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART) in a subject in need thereof, comprising administering to the subject the pharmaceutical composition as described herein. In some embodiments, the subject has congenital adrenal hyperplasia (CAH).
[0046] Provided herein is a method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, comprising administering to the subject the pharmaceutical composition as described herein.
[0047] CAH is a genetic, inherited disorder of the adrenal glands located above the kidneys. The adrenal glands are responsible for producing three types of hormones, cortisol, aldosterone, and androgens. Subjects with CAH cannot properly produce cortisol, and in some cases, are also unable to produce aldosterone. Another common issue is the production of too much of certain androgens, such as testosterone and 17-hydroxyprogesterone. The hormonal imbalances due to CAH can lead to serious illnesses, atypical genitalia, growth concerns and other issues. CAH can result in the symptoms described herein.
[0048] There are two major forms of CAH: classic CAH, and non-classic CAH. In classic CAH, the subject fails to produce sufficient cortisol which is useful for regulation of blood pressure, blood sugar, and helping the body respond to illness or injury. Some younger subjects with classical CAH are also unable to secrete aldosterone or maintain adequate amounts of salts in their bodies. This can lead to severe dehydration, and even death.
[0049] In non-classic CAH, the body makes enough cortisol, but over produces certain androgens such as testosterone and 17 -hydroxy progesterone. This is the most common form of CAH, and the mild form compared to classic CAH.
[0050] In some embodiments, the CAH is classic CAH. In some embodiments, the CAH is non-classic CAH.
[0051] Provided herein is a method of improving hyperandrogenic systems in a subject in need thereof, comprising administering to the subject the pharmaceutical composition described herein. Hyperandrogenism occurs when there is an excessive amount of androgens in the subject. It commonly affects females, and can cause acne, alopecia, irregular periods, and hirsutism. In some embodiments, the hyperandrogenic systems are selected from the group consisting of acne, hirsutism, and alopecia.
[0052] Provided herein is a method of treating menstrual irregularity, ovulatory dysfunction or infertility, in a subject in need thereof, comprising administering to the subject the pharmaceutical composition described herein. The menstrual irregularity, ovulatory dysfunction, or infertility can be due to CAH.
[0053] Provided herein is a method of improving metabolic symptoms in a subject in need thereof, comprising administering to the subject the pharmaceutical composition described herein. The metabolic symptoms can be due to CAH. In some embodiments, the metabolic symptoms are selected from the group consisting of body weight, BMI, fat mass, waist circumference, blood pressure and glycemic control.
[0054] Provided herein is a method of treating polycystic ovary syndrome with functional ovarian hyperandrogenism and functional adrenal hyperandrogenism (PCOS-FOH + FAH) in a subject in need thereof, comprising administering to the subject the pharmaceutical composition described herein. The PCOS-FOH + FAH can be due to CAH.
[0055] Provided herein is a method of treating polycystic ovary syndrome with functional adrenal hyperandrogenism (PCOS-FAH) in a subject in need thereof, administering to the subject the pharmaceutical composition described herein. The PCOS-FAH can be due to CAH.
[0056] Provided herein is a treating endometriosis or improving the symptoms of endometriosis in a subject in need thereof, comprising administering to the subject the pharmaceutical composition described herein. Endometriosis can be due to CAH.
[0057] Treating endometriosis or improving the symptoms can improve the symptoms for the pain experienced. In some embodiments, the administration of the pharmaceutical composition improves the symptom of pain experienced by the subject. In someembodiments, wherein the administration of the pharmaceutical composition reduces the symptom of pain experienced by the subject. In some embodiments, the administration of the pharmaceutical composition prevents the symptom of pain experienced by the subject. In some embodiments, the administration of the pharmaceutical composition eliminates the symptom of pain experienced by the subject.
[0058] The pharmaceutical composition can be administered in any suitable dosage of Compound 1 for the methods described herein, for example from about 1 mg / day to about 2000 mg / day. In some embodiments, the pharmaceutical composition is administered at a dose of from about 5 mg / day to about 1000 mg / day of Compound 1. In some embodiments, the pharmaceutical composition is administered ata dose of from about 10 mg / day to about 500 mg / day of Compound 1. In some embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg / day to about 200 mg / day of Compound 1. In some embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg / day to about 100 mg / day of Compound 1. In some embodiments, the pharmaceutical composition is administered at a dose of from about 10 mg / day to about 70 mg / day of Compound 1. In some embodiments, the pharmaceutical composition is administered at a dose of from about 25 mg / day to about 50 mg / day of Compound 1.
[0059] The pharmaceutical composition for administered to the methods described herein can be administered at any suitable interval. In some embodiments, the pharmaceutical composition is administered at least once per day. In some embodiments, the pharmaceutical composition is administered twice per day. In some embodiments, the pharmaceutical composition is administered once per day. In some embodiments, the pharmaceutical composition is administered once per day for one week. In some embodiments, the pharmaceutical composition is administered once per day for two weeks. In some embodiments, the pharmaceutical composition is administered once per day for three weeks. In some embodiments, the pharmaceutical composition is administered once per day for four weeks. In some embodiments, the pharmaceutical composition is administered weekly. In some embodiments, the pharmaceutical composition is administered biweekly. In some embodiments, the pharmaceutical composition is administered monthly.
[0060] The pharmaceutical composition can be administered at any suitable time, such as during a fed state or a fasting state. In some embodiments, the pharmaceutical composition can be administered in a fed state. In some embodiments, the pharmaceutical composition is administered in a fasting state.
[0061] The pharmaceutical composition described herein may further comprise an additional therapeutic agent. In some embodiments, the methods described herein further comprising administering to the subject an additional therapeutic agent. The additional therapeutic agent can be administered concurrently or separately.
[0062] In some embodiments, the additional therapeutic agent is glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen agent. In some embodiments, the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone. In some embodiments, the mineralocorticoid is fludrocortisone. In some embodiments, the additional therapeutic agent is an CRFi antagonist. In some embodiments, the additional therapeutic agent is crinecerfont. The methods described herein for formulation of a pharmaceutical composition and methods of treatment can also be applied to crinecerfont.
[0063] In some embodiments, the method further comprises more than one dose of glucocorticoid, wherein a dose of a glucocorticoid is reduced compared to a previously received dose of the glucocorticoid. In some embodiments, the dose of glucocorticoid is reduced by at least 5% to at least 30%. In some embodiments, the dose of glucocorticoid is reduced by at least 5% to at least 25%. In some embodiments, the dose of glucocorticoid is reduced by at least 5% to at least 20%. In some embodiments, the dose of a glucocorticoid is reduced by at least 5%. In some embodiments, the dose of a glucocorticoid is reduced by at least 10%. In some embodiments, the dose of a glucocorticoid is reduced by at least 15%. In some embodiments, the dose of a glucocorticoid is reduced by at least 20%.
[0064] In some embodiments, the dose of a glucocorticoid is reduced by at least 5 mg to 25 mg hydrocortisone equivalents. In some embodiments, the dose of a glucocorticoid is reduced by at least 5 mg to 20 mg hydrocortisone equivalents. In some embodiments, the dose of a glucocorticoid is reduced by at least 5 mg hydrocortisone equivalents. In some embodiments, the dose of a glucocorticoid is reduced by at least 10 mg hydrocortisone equivalents. In some embodiments, the dose of a glucocorticoid is reduced by at least 15 mg hydrocortisone equivalents. In some embodiments, the dose of a glucocorticoid is reduced by at least 20 mg hydrocortisone equivalents.
[0065] In some embodiments, the methods described herein further comprising an additional treatment selected from surgical resection of the tumors and radiation therapy, or a combination thereof. In some embodiments, the additional therapy is surgical resection and the surgical resection is prior to, after, and / or concurrent with administration of the pharmaceutical composition described herein. In some embodiments, the additional treatmentis radiation therapy and the radiation therapy is prior to, after, and / or concurrent with administration of the pharmaceutical composition described herein.
[0066] The subject can be at any suitable age for the methods described herein. In some embodiments, the subject is from about 5 years of age to about 70 years of age. In some embodiments, the subject is from about 8 years of age to about 55 years of age. In some embodiments, the subject is from about 8 years of age to about 35 years of age. In some embodiments, the subject is from about 8 years of age to about 25 years of age. In some embodiments, the subject is from about 9 years of age to about 18 years of age.
[0067] Provided herein is a use of a pharmaceutical composition described herein, in the manufacture of a medicament for the treatment of congenital adrenal hyperplasia (CAH).Definitions
[0068] Unless defined otherwise, all terms of art, notations and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.
[0069] Throughout this application, various embodiments may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.
[0070] As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a sample” includes a plurality of samples, including mixtures thereof.
[0071] The term “pharmaceutically acceptable excipient” as used herein, refers a material, such as a carrier, diluent, or formulation, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic, i.e., the material may beadministered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
[0072] The term “loss on drying” refers to a typical method for determining the moisture content of a sample, such as a solid. Loss on drying includes removal of not only water, but any volatile matter. It is typically reported as a percentage of w / w resulting from the loss of water and the volatile matter.
[0073] Granules” for pharmaceutical compositions refer to dosage forms of solid dry aggregates of powder particles which are typically spherical in shape. They may contain one or more Active Pharmaceutical Ingredients (APIs), and are frequently compacted into tablets or filled into capsules. Granules are typically in the 4- to 12- mesh sieve size range, although various sizes can be prepared. Granules can be formed by various granulation methods such as by dry granulation or by wet granulation.
[0074] The term “dry granulation” refers to a process of forming granules without using a liquid or organic solvent. Dry granulation methods typically use mechanical compression to form slugs or compaction, such as roller compaction, to facilitate assemblage of the dry powder particles or powder blends. The agglomeration of these dry particles or blends can then be milled to obtain granules.
[0075] The term “wet granulation” refers to a process of forming granules using granulation liquids such as organic solvents with or without binders to facilitate formation of wet mass by adhesion. The wet mass is then dried and milled to obtain the granules. Wet granulation is the most widespread granulation technique used.
[0076] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.EXAMPLES
[0077] The following illustrative examples are representative of embodiments of the stimulation, systems, and methods described herein and are not meant to be limiting in any way.
[0078] The drug sub stance tildacerfont(SPNOOl) oxalic acid co-crystal is very cohesive and bulky and as a result demonstrated poor / passable flow properties. The formulations developed with different approaches were evaluated for flow properties, dissolution and XRD analysis. With the direct blending approach, the selected excipients to the drug were kept at 1 :3 to 1 :4 ratio and evaluated for flow properties and dissolution. The powder blend flow properties did not improve significantly however, it was feasible to fill the capsules. Thepowder blend when tested for dissolution exhibited a slower drug release profile and XRD analysis showed polymorph conversion to the parent compound (SPN001).
[0079] For the dry granulation approach, the powder blend was compressed into slugs using the compression machine and milled using co-mill. The resulting granules flow properties did improve and were feasible to fill the capsules. The granules when tested for dissolution demonstrated a better drug release profile than the dry blending approach however still slower to meet the proposed specification of Q >80% at 45 minutes. The XRD analysis also showed polymorph conversion to the parent compound (SPN001).
[0080] With the wet granulation approach the selected excipients were granulated using a solvent and dried in the oven followed by milling using co-mill. The resulting granules demonstrated good flow properties compared to the other approaches evaluated and also the granules demonstrated better drug release profile. However, the XRD analysis showed polymorph conversion to the parent compound (SPN001).Example 1. Excipient Compatibility
[0081] The excipients utilized were either USP / NF grade materials and their selection was based on the functionality in the respective formulation. Upon identifying the list of excipients to be utilized in the development work, excipient compatibility study was conducted using 1 :1 or 1 :3 ratio. The table below shows the list of excipients utilized for excipient compatibility study.*Capsule shell is crushed by using mortar and pestle and the resulting mixture was used for excipient compatibility study
[0082] Sample set-up: The selected excipient and drug substance as indicated in the below table were accurately weighed into a 40 mL clear glass vial respectively. All the samples were stored in a stability chamber at 40°C / 75%RH and in hot air oven at 60°C for 2 weeks and 4 weeks, while the initial samples were stored at room temperature conditions. For binary mixtures, duplicate samples were prepared at each timepoint and for each condition.Table 2: Binary mixtures for excipient compatibility study
[0083] Test results: The samples were pulled at 2 weeks and 4 weeks from oven at 60°C and 40°C / 75%RH conditions and evaluated for physical and chemical stability. The samples are free flowing and no change in color was observed. The chemical stability results are reported in the table below.Table 3: Excipient compatibility study results for SPN-001 oxalic acid cocrystalthe results.
[0084] SPN001 Oxalic acid cocrystal appeared to be compatible with most of the selected excipients. Increase in total impurities (TOTAL IMP) were observed with citric acid, silicon dioxide and povidone at 4 weeks 40°C / 75%RH condition. At 60°C condition total impurities increased with silicon dioxide and sodium lauryl sulfate at the 4 weeks time point. These observations were taken into consideration for formulation development.Example 2. Formulation Development
[0085] Development of three prototype formulations of tildacerfont (SPN001) oxalic acid co-crystal capsule 50 mg strength at lab scale by improving the flosw properties of the drug substance are analyzed. The drug substance, SPN001 oxalic acid is a micronized powder with D90 of <10p as per the manufacturer’s Co A and is very cohesive and bulky with poor flow properties. Hence, to improve the flow three different approaches were adopted to formulate the drug product.Table 4: Drug substance flow property
[0086] The three methods are as follows:
[0087] 1. Direct blending: Blending the drug substance along with other excipients and filling into a capsule.
[0088] 2. Dry granulation (Slugging): Blending the drug substance along with other excipients and making into slugs followed by milling and filling the granules into a capsule
[0089] 3. Wet granulation (using organic solvent): As the drug substance is not stable in aqueous medium, granulation using organic solvent is utilized followed by drying and milling. The milled granules are filled into the capsule.
[0090] Raw materials: the following table shows the list of raw materials utilized for formulation development.Table 5: List of raw materials
[0091] Approach I - Direct blending: The selected raw materials for each batch were screened through 20 mesh followed by blending. Multiple batches were manufactured by altering the composition and evaluated for flow properties and the results are shown in the table below.Table 6: Batches manufactured using direct blending approach
[0092] As seen from the data above for the formulations evaluated, the powder blends exhibited poor flow properties which could result in non-uniformity and capsule fill weight variation. Hence, this approach was not considered for further development work.
[0093] Approach II - Dry granulation: For the dry blending approach, the selected raw materials for each batch were screened through 20 mesh along with drug substance followed by blending. The powder blend was compressed into slugs using a rotary tablet press and resulting slugs were milled using co-mill fitted with 7L032R02528*(813) screen followed by filling the granules into the capsules. Multiple batches were manufactured by altering the composition and evaluated for flow properties.Table 7: Batches manufactured using dry granulation approach
[0094] As seen from the data above for the formulations evaluated the flow properties improved from poor / passable to fair with the dry granulation approach.
[0095] Approach III - Wet granulation: For the wet granulation approach the raw materials for each batch were screened through 20 mesh along with drug substance and loaded into the high shear granulator. As the drug substance is soluble in water, ethanol (200 proof) was selected as a solvent for granulation. Once the granulation is complete the granules were dried in an oven at 60°C until the moisture content is below 2.0%. The dried granules were milled using a co-mill fitted with two different screens7L050G03119B*(1270), 7L032R02528(813) and evaluated for granules flow properties and finally filled into capsules. Not many batches could be manufactured using the wet granulation approach due to the potential for the cocrystal to convert to the parent compound (SPN001). The batches manufactured and the evaluated flow properties are shown in the table below.Table 8: Batches manufactured using wet granulation approach
[0096] Based on the results the wet granulation approach appears to show better flow properties among all the approaches evaluated. However, the tildacerfont oxalic acid cocrystal has some degree of solubility in all known solvents. There is a potential to convert to the parent compound.Example 3. XRD analysis
[0097] To evaluate for any potential polymorph conversion initially only the wet and dry granulation samples along with the corresponding placebo samples were tested by H&M Analytical service labs. The parent compound (SPN001) was also tested for reference.
[0098] Experimental conditions: XRD study samples were placed into zero background sample holders and put into an analytical X'pert powder diffractometer (S / N 201772) using Cu radiation at45KV / 40mA. The scans were then run with a fixed, fine slit arrangement over the range of 3° - 50° with a step size of 0.0167° and an accumulated counting time of 250 seconds per step and respective results are reported.
[0099] Samples evaluated with their corresponding formulation composition is listed below.
[0100] 1. SPN001 oxalic acid cocrystal (Lot#2523HYD10010322)
[0101] 2. SPN001 (Lot#CR-C07102401-FF2002M-RS)
[0102] 3. RB0068-018 (drug product manufactured using wet granulation approach)
[0103] 4. RB0068-018 (placebo blend for wet granulation approach)
[0104] 5. RB0068-019 (drug product manufactured using dry granulation approach)
[0105] 6. RB0068-019 (placebo blend for dry granulation approach)Table 9: Formulation composition for Dry and Wet granulation
[0106] XRD lab showed that wet granulated drug product (Lot# RB0068-018) appears to contain SPN001 along with SPN001 oxalic acid cocrystal.
[0107] XRD lab concluded that the dry granulated drug product (Lot# RB0068-019) appears to contain peaks that are associated with drug substance SPN001 along with SPN001 oxalic acid cocrystal.
[0108] Based on the results, as there was polymorph conversion in both the wet granulation and dry granulation samples, it was decided to test the powder blend (before slugging) alone for dry granulation approach to verify if the compression has any impact on the polymorph conversion. Below is the list of samples tested for XRD analysis.
[0109] 1. RB0068-023 (dry granulation blend (same as RB0068-019) before slugging)
[0110] 2. RB0068-002 (SPN001 oxalic acid cocrystal, 4-week 60°C sample)
[0111] 3. RB0068-024A (SPN001 oxalic acid crystal after slugging)
[0112] 4. RB0068-24B (dry granulation placebo blend (for RB0068-019) after slugging)
[0113] The test results concluded that the samples (before slugging) and after slugging appear to contain peaks that are associated with SPN001 and SPN001 oxalic acid cocrystal confirming that there is polymorph conversion. The tildacerfont oxalic acid cocrystal after slugging and forced degradation sample did not show any polymorph conversion.
[0114] After evaluating the results, it was concluded that the adsorbed moisture in the formulation could trigger for the polymorph conversion to the parent compound (SPN001) hence it was decided to evaluate low moisture excipients for formulating the drug product. As the powder flow properties did not improve with the dry blending approach and as the drug substance is soluble in majority of the solvents for wet granulation approach triggering for polymorph conversion, it was decided to focus on the dry granulation approach. The table below shows the moisture comparison between the high moisture and low moisture excipients evaluated.Table 10: Excipient moisture content comparisonblending approach using low moisture excipients.
[0116] The formulations evaluated with low moisture excipients containing with and without silicon dioxide, all exhibited peaks that are associated with the drug substance and SPN001 samples confirming that there is polymorph conversion.
[0117] The formulations evaluated (RB0068-026A, B, 027A, B) with low moisture excipients containing with and without silicon dioxide, all exhibited peaks that are associated with the drug substance and SPN001 samples confirming that there is polymorph conversion.
[0118] After evaluating the test results, it was concluded that apart from the moisture there could be some excipient in the formulation which could contribute to the polymorph conversion as both the high moisture and low moisture excipients exhibited the same phenomenon. Hence, to understand which excipient in the formulation could cause the polymorph conversion, a few binary mixtures of drug and commonly used excipients were prepared and submitted for XRD analysis. The table below shows the list of excipients selected and the corresponding ratio evaluated.Table 12. Binary mixture samples
[0119] The binary mixtures evaluated all demonstrated tiny peaks (especially between13-14 degrees and at 19.5 degrees) which corresponds to the parent compound SPN001.Example 4. Dissolution analysis
[0120] Drug release profiles of the prototype formulations were evaluated using 900 mL of 0.1N HC1 with 0.3% SLS using apparatus II at 50 rpm. The prototype formulations (dry granulation & wet granulation) evaluated were filled into the capsule size 1 and tested for drug release for up to 60 minutes.Table 13: Drug release profiles for different approaches
[0121] The drug release for batches manufactured using wet granulation approach demonstrated faster dissolution compared to the batches manufactured using dry granulation approach.
[0122] To understand if the drug release is impacted by the formulation ordrug substance alone, dissolution studies were conducted for both SPN001 and SPNOOl oxalic acid cocrystal compounds at 50 mg dose strength by filling in to Capsule size 00 and the results are shownin the table below. The drug release was evaluated using 900 mL of 0.1NHC1 with 0.3% SLS using apparatus II. For the first 60 minutes of the dissolution the paddle speed was maintained at 50 rpm and changed to 100 rpm from 60 to 80 minutes followed by 250 rpm for 80-95 minutes.Table 14: Drug release profiles for SPN001 and SPN001 oxalic acid cocrystal
[0123] The drug release from SPN001 oxalic acid cocrystal appears to be slower than SPN001 concluding that the SPN001 oxalic acid cocrystal is more hydrophobic. Also, in the dissolution vessel SPN001 is well dispersed compared to SPN001 oxalic acid cocrystal as it formed clumpsin the dissolution vessel. This observation is consistent with the drug release.
[0124] The granules from the wet granulation approach demonstrated better flow properties compared to dry granulation approach followed by dry blending approach. Based on XRD analysis all samples evaluated using different approaches exhibited peaks that appear to be consistent with the SPN001 sample concluding that there is a polymorph conversion. The drug release for the formulations manufactured using the wet granulation approach demonstrated faster release profiles compared to the dry granulation approach. Drug product chemical stability could not be evaluated as all the prototype formulations evaluated exhibited polymorph conversion.
[0125] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims
CLAIMSWhat is claimed is:
1. A pharmaceutical composition comprising a co-crystal of Compound 1 and oxalic acid, and at least one pharmaceutically acceptable excipient, wherein the pharmaceutically acceptable excipient has a low moisture content of less than 5% loss on drying (LOD) w / w, wherein Compound 1 has the following structure:
2. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable excipient has a low moisture content of less than 3% LOD w / w.
3. The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable excipient has a low moisture content of less than 1% LOD w / w.
4. The pharmaceutical composition of any one of claims 1 to 3, wherein there are at least two pharmaceutically acceptable excipients.
5. The pharmaceutical composition of any one of claims 1 to 4, wherein there are at least three pharmaceutically acceptable excipients.
6. The pharmaceutical composition of any one of claims 1 to 5, wherein each pharmaceutically acceptable excipient is independently microcrystalline cellulose (MCC), sodium lauryl sulfate, copovidone, magnesium stearate, dicalcium phosphate anhydrous, or silicone dioxide.
7. The pharmaceutical composition of any one of claims 1 to 6, wherein the pharmaceutically acceptable excipient is microcrystalline cellulose (MCC), sodium lauryl sulfate, magnesium stearate, or dicalcium phosphate anhydrous.
8. The pharmaceutical composition of claim 6 or 7, wherein the MCC is Avicel PH 200 or Vivapur 14.
9. The pharmaceutical composition of claim 8, wherein the MCC is Vivapur 14.
10. The pharmaceutical composition of any one of claims 1 to 9, further comprising a moisture barrier between the co-crystal and the pharmaceutically acceptable excipient.
11. The pharmaceutical composition of claim 10, wherein the moisture barrier is a moisture barrier film coating.
12. The pharmaceutical composition of any one of claims 1 to 11, wherein Compound 1 is in an amount of about 10 mg to 250 mg.
13. The pharmaceutical composition of claim 12, wherein Compound 1 is in an amount of about 25 to 100 mg.
14. The pharmaceutical composition of claim 13, wherein Compound 1 is in an amount of about 50 mg.
15. The pharmaceutical composition of any one of claims 1 to 14, wherein the pharmaceutical composition is shelf-stable for at least 2 weeks.
16. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is shelf-stable for at least one month.
17. The pharmaceutical composition of any one of claims 1 to 16, wherein the cocrystal has an X-ray powder diffraction pattern (XRPD) comprising peaks at 10.84 ± 0.2° 2- 9, 15.96 ± 0.2° 2-9, 23.44 ± 0.2° 2-9, and 24.80 ± 0.2° 2-9, and as measured by XRPD using an X-ray wavelength of 0.71073 A.
18. The pharmaceutical composition of claim 17, wherein the XRPD further comprises at least one peak selected from 5.44 ± 0.2° 2-9, 20.78 ± 0.2° 2-9, 22.74 ± 0.2° 2-9, 23.04 ± 0.2° 2-9, 26.80 ± 0.2° 2-9, and 28.86 ± 0.2° 2-9, and as measured by X-ray powder diffraction using an X-ray wavelength of 0.71073 A.
19. The pharmaceutical composition of claim 17, wherein the XRPD further comprises at least five peaks selected from 8.82 ± 0.2° 2-9, 11.70 ± 0.2° 2-9, 14.60 ± 0.2° 2- 9, 15.56 ± 0.2° 2-9, 16.70 ± 0.2° 2-9, 18.82 ± 0.2° 2-9, 19.18 ± 0.2° 2-9, 20.02 ± 0.2° 2-9, 20.50 ± 0.2° 2-9, 21.72 ± 0.2° 2-9, 25.52 ± 0.2° 2-9, 25.92 ± 0.2° 2-9, 26.94 ± 0.2° 2-9, and 28.00 ± 0.2° 2-9, and as measured by X-ray powder diffraction using an X-ray wavelength of 0.71073 A.
20. The pharmaceutical composition of any one of claims 1 to 19, wherein the cocrystal is characterized by differential scanning calorimetry (DSC) thermogram comprising an endotherm in the range of about 160 °C to 170 °C.
21. The pharmaceutical composition of claim 20, wherein the co-crystal is characterized by a DSC thermogram comprising an endotherm with an onset of about 164 °C and a peak of about 166 °C.
22. The pharmaceutical composition of any one of claims 1 to 21, wherein the pharmaceutical composition is in a capsule.
23. The pharmaceutical composition of claim 22, wherein the capsule is a hard gelatin capsule or hydroxyl propyl methyl cellulose (HPMC) capsule.
24. The pharmaceutical composition of claim 23, wherein the capsule is a hard gelatin capsule.
25. A method of preparing the pharmaceutical composition of any one of claims 1 to 24, the method comprising mixing a solid co-crystal of Compound 1 and oxalic acid with a solid pharmaceutically acceptable excipient to form a powder blend.
26. The method of claim 25, wherein the ratio of the pharmaceutically acceptable excipient to Compound 1 is about a 1 :1 to 1 :4 ratio.
27. The method of claim 26, wherein the ratio of the pharmaceutically acceptable excipient to Compound 1 is about a 1 :3 to 1 :4 ratio.
28. The method of claim 25, further comprising granulating the powder blend to form granules.
29. The method of claim 28, wherein the granules are formed by dry granulation.
30. The method of claim 29, wherein dry granulation comprises compressing the powder blend into slugs.
31. The method of claim 30, wherein the powder blend is compressed using a compression machine and milled using co-mill.
32. The method of claim 28, wherein the granules are formed by wet granulation.
33. The method of claim 32, wherein wet granulation comprises:(a) using a solvent on the powder blend; then(b) drying in the oven; and(c) milled using co-mill to form the granules.
34. The method of any one of claims 28 to 33, wherein the granules are filled in a capsule.
35. The method of claim 34, wherein the capsule is a hard gelatin capsule or hydroxyl propyl methyl cellulose (HPMC) capsule.
36. The method of claim 35, wherein the capsule is a hard gelatin capsule.
37. A method of treating testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART) in a subject in need thereof, comprising administering to the subject the pharmaceutical composition as described in any one of claims 1 to 24.
38. The method of claim 37, wherein the subject has congenital adrenal hyperplasia (CAH).
39. A method of treating congenital adrenal hyperplasia (CAH) in a subject in need thereof, comprising administering to the subject the pharmaceutical composition as described in any one of claims 1 to 24.
40. The method of claim 39, wherein the CAH is classic CAH.
41. The method of claim 39, wherein the CAH is non-classic CAH.
42. A method of improving hyperandrogenic systems in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of any one of claims 1 to 24.
43. The method of claim 42, wherein the hyperandrogenic systems are selected from the group consisting of acne, hirsutism, and alopecia.
44. A method of treating menstrual irregularity, ovulatory dysfunction or infertility, in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of any one of claims 1 to 24.
45. A method of improving metabolic symptoms in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of any one of claims 1 to 24.
46. The method of claim 45, wherein the metabolic symptoms are selected from the group consisting of body weight, BMI, fat mass, waist circumference, blood pressure and glycemic control.
47. A method of treating polycystic ovary syndrome with functional ovarian hyperandrogenism and functional adrenal hyperandrogenism (PCOS-FOH + FAH) in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of any one of claims 1 to 24.
48. A method of treating polycystic ovary syndrome with functional adrenal hyperandrogenism (PCOS-FAH) in a subject in need thereof, administering to the subject the pharmaceutical composition of any one of claims 1 to 24.
49. A method of treating endometriosis or improving the symptoms of endometriosis in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of any one of claims 1 to 24.
50. The method of claim 49, wherein the administration of the pharmaceutical composition improves the symptom of pain experienced by the subject.
51. The method of claim 49, wherein the administration of the pharmaceutical composition reduces the symptom of pain experienced by the subject.
52. The method of claim 49, wherein the administration of the pharmaceutical composition prevents the symptom of pain experienced by the subject.
53. The method of claim 49, wherein the administration of the pharmaceutical composition eliminates the symptom of pain experienced by the subject.
54. The method of any one of claims 37 to 53, wherein the pharmaceutical composition is administered at a dose of from about 5 mg / day to about 1000 mg / day of Compound 1.
55. The method of any one of claims 37 to 54, wherein the pharmaceutical composition is administered in a fed state.
56. The method of any one of claims 37 to 54, wherein the pharmaceutical composition is administered in a fasted state.
57. The method of any one of claims 37 to 56, wherein the pharmaceutical composition is administered at least once per day.
58. The method of any one of claims 37 to 57, further comprising administering to the subject an additional therapeutic agent.
59. The method of claim 58, wherein the additional therapeutic agent is glucocorticoid, a mineralocorticoid, an ACAT1 inhibitor, or an anti-androgen agent.
60. The method of claim 59, wherein the glucocorticoid is beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, or triamcinolone.
61. The method of claim 59, wherein the mineralocorticoid is fludrocortisone.
62. The method of claim 58, wherein the additional therapeutic agent is an CRFi antagonist.
63. The method of any one of claims 37 to 62, further comprising an additional treatment selected from surgical resection of the tumors and radiation therapy, or a combination thereof.
64. The method of claim 63, wherein the additional therapy is surgical resection and the surgical resection is prior to, after, and / or concurrent with administration of the pharmaceutical composition of any one of claims 1 to 24.
65. The method of claim 63, wherein the additional treatment is radiation therapy and the radiation therapy is prior to, after, and / or concurrent with administration of the pharmaceutical composition of any one of claims 1 to 24.
66. The method of any one of claims 37 to 65, wherein the subject is from about 8 years of age to about 55 years of age.
67. The method of any one of claims 66, wherein the subject is from about 9 years of age to about 18 years of age.
68. Use of a pharmaceutical composition of any one of claims 1 to 24, in the manufacture of a medicament for the treatment of congenital adrenal hyperplasia (CAH).
69. The method of any one of claims 37 to 67, further comprises more than one dose of glucocorticoid, wherein a dose of a glucocorticoid is reduced compared to a previously received dose of the glucocorticoid.
70. The method of claim 69, wherein the dose of a glucocorticoid is reduced by at least 5%.
71. The method of claim 70, wherein the dose of a glucocorticoid is reduced by at least 10%.
72. The method of claim 71 , wherein the dose of a glucocorticoid is reduced by at least 15%.
73. The method of claim 72, wherein the dose of a glucocorticoid is reduced by at least 20%.
74. The method of claim 69, wherein the dose of a glucocorticoid is reduced by at least 5 mg hydrocortisone equivalents.
75. The method of claim 74, wherein the dose of a glucocorticoid is reduced by at least 10 mg hydrocortisone equivalents.
76. The method of claim 75, wherein the dose of a glucocorticoid is reduced by at least 15 mg hydrocortisone equivalents.
77. The method of claim 76, wherein the dose of a glucocorticoid is reduced by at least 2- mg hydrocortisone equivalents.
78. The pharmaceutical composition or method of any one of the preceding claims, further comprising CRF1 antagonist crinecerfont.
Citation Information
Patent Citations
Corticotropin releasing factor receptor antagonists
US20200255436A1
Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023091684A1
